82872-99-9 Usage
Description
Ethyl 3-(4-Methoxyphenoxy)propanoate is an organic compound that serves as a key intermediate in the synthesis of phenoxypropionic acid derivatives. These derivatives exhibit nematocidal properties, making them valuable in the development of effective treatments against parasitic nematodes.
Uses
Used in Pharmaceutical Industry:
Ethyl 3-(4-Methoxyphenoxy)propanoate is used as a research reagent for the preparation of phenoxypropionic acid derivatives with nematocidal properties. These derivatives are crucial in the development of new drugs and treatments targeting parasitic nematodes, which can cause significant health and economic problems in both humans and animals. ethyl 3-(4-Methoxyphenoxy)propanoate's role in creating nematocidal agents contributes to the advancement of pharmaceutical research and the discovery of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 82872-99-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,2,8,7 and 2 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 82872-99:
(7*8)+(6*2)+(5*8)+(4*7)+(3*2)+(2*9)+(1*9)=169
169 % 10 = 9
So 82872-99-9 is a valid CAS Registry Number.
82872-99-9Relevant articles and documents
The synthesis and evaluation of phenoxyacylhydroxamic acids as potential agents for Helicobacter pylori infections
Ni, Wei-Wei,Liu, Qi,Ren, Shen-Zhen,Li, Wei-Yi,Yi, Li-Li,Jing, Heng,Sheng, Li-Xin,Wan, Qin,Zhong, Ping-Fu,Fang, Hai-Lian,Ouyang, Hui,Xiao, Zhu-Ping,Zhu, Hai-Liang
supporting information, p. 4145 - 4152 (2018/07/13)
Two series of ω-phenoxy contained acylhydroxamic acids as novel urease inhibitors were designed and synthesized. Biological activity evaluations revealed that ω-phenoxypropinoylhydroxamic acids were more active than phenoxyacetohydroxamic acids. Out of these compounds, 3-(3,4-dichlorophenoxy)propionylhydroxamic acid c24 showed significant potency against urease in both cell free extract (IC50 = 0.061 ± 0.003 μM) and intact cell (IC50 = 0.89 ± 0.05 μM), being over 450- and 120-fold more potent than the clinically prescribed urease inhibitor AHA, repectively. Non-linear fitting of experimental data (V-[S]) suggested a mixed-type inhibition mechanism and a dual site binding mode of these compounds.